CLOSTRIDIUM DIFFICILE TOXIN B RIBOTYPE 027

Clostridium difficile Toxin B ribotype 027, manufactured by The Native Antigen Company, is a highly purified preparation of Toxin B from the hypervirulent ribotype 027 of Clostridium difficile (C. difficile). Developed for use in vaccine research, serology based assays and cytotoxicity testing. The product is presented in a choice of pack sizes and is lyophilised for ease of use.

PRODUCT DETAILS – CLOSTRIDIUM DIFFICILE TOXIN B RIBOTYPE 027

Native Clostridium difficile Toxin B, ribotype 027, strain R20291.
Greater than 95% purity and stored in 0.05M hepes, 0.15M NaCl, 5% sucrose.

BACKGROUND

Clostridium difficile is a gram positive spore-forming anaerobic bacterium, which was first described in the mid-1930s. Recent studies have shown that C. difficile is predominantly associated with cases of infectious diarrhoea in patients that have been treated with antibiotics (antibiotic-associated diarrhoea AAD), or have disrupted commensal gastrointestinal flora. C. difficile infection can cause severe disease and death in a significant number of cases and is recognised as a leading cause of severe gastrointestinal disease and AAD in hospitalised patients (Voth, DE). The severity of the disease in each case is determined by the virulence of the C. difficile strain, the condition of the patient’s normal gut flora and the individual’s immune response to intestinal damage.

Toxins A and B have been identified as major C. difficile virulence factors, which are encoded by the tcdA and tcdB genes respectively. Both toxin A and toxin B have pro-inflammatory and cytotoxic activity, which cause disruption to the intestinal epithelium leading to extensive damage and cell death in the large intestine (Carter, GP).

In recent years, new hypervirulent strains of C. difficile, including ribotype 027 and 078, have emerged causing new epidemics of C. difficile in the developed world, and are a cause for significant concern within the global health care community (Ghose, C).

REFERENCES

Voth, DE et al. (2005). Clostridium difficile Toxins: Mechanism of Action and Role in Disease. Clin Microbiol Rev.18(2): 247–263.
Carter, GP et al (2010). The role of toxin A and toxin B in Clostridium difficile-associated disease. Past and present perspectives. Gut Microbes.1(1): 58–64.
Ghose, C. (2013). Clostridium difficile infection in the twenty-first century. Emerg Microbes Infect.2(9): e62.

Certificate of analysisSafety Datasheet

Ambient

品牌介绍

Native Antigen Company专业从事天然和重组病毒和细菌抗原，抗体和免疫测定的开发和生产，以及定制产品的开发和定制生产。该公司通过其专有的哺乳动物细胞表达系统在生产高质量蛋白质方面拥有数十年的经验，可确保正确的糖基化和正确的折叠。在领先的疫苗研究和血清学中，正确的折叠和糖基化至关重要的领先制药，体外诊断测定制造商和学术团体广泛采用了Native Antigen Company的高质量试剂。